Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia:: results of a multicentre, double-blind study (the Amisulpride Study Group)

被引:74
作者
Carrière, P
Bonhomme, D
Lempérière, T
机构
[1] Serv Med Psychol Reg, F-36021 Chateauroux, France
[2] Sanofi Synthelabo France, F-92352 Le Plessis Robinson, France
关键词
amisulpride; antipsychotic; atypical antipsychotic; haloperidol; schizophrenia;
D O I
10.1016/S0924-9338(00)00401-6
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months. More patients in the haloperidol group withdrew prematurely (44% vs 26%; P = 0.0077) due to a higher incidence of adverse events. Amisulpride was at least as effective as haloperidol in reducing the Brief Psychiatric Rating Scale (BPRS) total score (-27.3 vs -21.9) (non-inferiority test; P < 0.001). The PANSS positive score improved to a similar extent in both groups whilst improvement in the PANSS negative score was significantly greater with amisulpride (-10.5 vs -7.2; P = 0.01). The percentage of responders on the Clinical Global impression scale was also significantly greater with amisulpride (71% vs 47%; P < 0.001). Both the Quality of Life Scale (QLS) and the Functional Status Questionnaire (FSQ) improved to a significantly greater extent under amisulpride. Haloperidol was associated with a greater incidence in extrapyramidal symptoms and with a greater increase in the Simpson-Angus score than was seen with amisulpride (0.32 vs 0.02; P < 0.001). In conclusion, amisulpride is globally superior to haloperidol in the treatment of acute exacerbations of schizophrenia and significantly improves patients' quality of life and social adjustment. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:321 / 329
页数:9
相关论文
共 37 条
[1]   Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo [J].
Arvanitis, LA ;
Miller, BG ;
Borison, RL ;
Pitts, WM ;
Sharif, ZA ;
Hamner, MB ;
Herz, MI ;
True, JE ;
Velligan, D ;
Knesevich, MA ;
Small, J ;
Steinbook, R ;
Hertzman, M ;
Keck, PE ;
Newcomer, JW ;
Grace, J ;
Rotrosen, J ;
Tandon, R ;
Dott, SG ;
Ferguson, JM ;
Addington, DEN ;
MacEwan, GW ;
Nair, VNP ;
Shriqui, CL ;
Williams, R ;
Daniel, DG ;
Shehi, GM ;
Patterson, WM ;
Merideth, CH .
BIOLOGICAL PSYCHIATRY, 1997, 42 (04) :233-246
[2]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[3]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[4]   Motor and mental aspects of extrapyramidal syndromes [J].
Casey, DE .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :105-114
[5]  
Chabannes JP, 1998, ENCEPHALE, V24, P386
[6]   Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol [J].
Chouinard, G ;
Albright, PS .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (04) :298-307
[7]  
CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25
[8]  
COLE JO, 1966, PSYCHIATRIC DRUGS, P153
[9]  
*COLL WORK GROUP C, 1998, J CLIN PSYCHIAT S12, V59, P3
[10]  
*COLL WORK GROUP C, 1998, J CLIN PSYCHIAT S12, V59, P35